Lazard Capital Market's Tom Galluci issued an update on flu activity Monday morning following a note from December 17th which suggested CVS (NYSE: CVS) and Walgreen (NYSE: WAG) could benefit from increased cases of the virus.
The analyst said flu activity was up 12 percent from last week and up a very concerning 94 percent from the same week last year. Prescriptions for cold, cough and/or flu drugs has surged 61 percent from December 2011.
Galluci believes this increase in activity is likely to have a greater effect on hospital volume metrics rather than earnings as a lower-margin business.
Lazard maintains a Buy rating on CVS and a Neutral rating on Walgreen shares.(c) 2012 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.